James C. Powers
Chairman and CEO
“I enjoy working with innovative scientists who think differently and are changing the way the biopharmaceutical industry approaches drug R&D.”
James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Mr. Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization of more than 3,000 employees. Mr. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. He was an advisor to the Coulter Translational Research Partnership in Biomedical Engineering at the University of Virginia where he met Drs. Blackman and Wamhoff. He currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Mr. Powers received a BS in Administration and Management Science from Carnegie-Mellon University.
Brian M. Campbell, Ph.D.
Vice Chairman, Chief Financial Officer, and Chairman of the Audit Committee
“I don’t work at HemoShear. I live HemoShear.”
Dr. Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President of their Washington office in 1973. In 1977, he co-founded Midway Airlines, Inc., the first new start-up carrier after airline deregulation, where he served as CFO and participated in the raising of venture capital to fund the airline’s launch. He returned to the aviation consulting business in 1983 and is currently chairman of The Campbell-Hill Aviation Group in Alexandria, VA. He has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. He currently serves as vice chairman and acting CFO of Dynamic Literacy, LLC; advisor to Targeson, LLC, a University of Virginia (UVa)-based biotechnology company; advisor and investor in BioMotion Analytics, LLC; is a member of the advisory board of UVa’s Heart and Vascular Center, and serves on the UVa Patent Foundation Advisory Panel. He earned a Bachelor of Commerce from McGill University, an MBA from the University of Western Ontario, and a PhD in Business Administration from Columbia University.
Brett R. Blackman, Ph.D.
Chief Scientific Officer
“Since our inception, HemoShear has been about providing transformative solutions using human relevant systems for our drug developing partners and supporting our collective mission in providing safe and effective therapies to improve global human health.”
Dr. Blackman is co-founder of HemoShear and co-inventor of its technology. He is a tenured Associate Professor in the Department of Biomedical Engineering at the University of Virginia (UVa) where since August 2002 he has led an NIH-funded research program investigating the role of the hemodynamic environment in regulating vascular endothelial cell biology in atherosclerosis. Prior to joining UVa Dr. Blackman trained as a postdoctoral research fellow in the Vascular Research Division of Brigham & Women’s Hospital and Harvard Medical School, where he developed the first cell-culture system to simulate human hemodynamic patterns on isolated human endothelial cells. This work laid the foundation for current research identifying the importance of precise hemodynamic conditions for regulating arterial vascular biology. Dr. Blackman has published more than twenty peer-reviewed articles, was a co-editor of Hemodynamics and Mechanobiology of the Endothelium, is a member of the Robert M. Berne Cardiovascular Research Center, is a peer reviewer for more than twelve scientific journals, served on UVa’s School of Engineering and Sciences Dean’s Research Advisory Committee, and was a standing member of the American Heart Association Bioengineering & Biotechnology study section. He obtained a BS in Mechanical Engineering from Drexel University and a PhD in Bioengineering from the University of Pennsylvania.
For a list of publications by Brett R. Blackman, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=blackman%20br.
Brian R. Wamhoff, Ph.D.
Vice President of Research and Development
“Our scientific teams are amazing, the science is translational, and I have never worked in a more exciting environment!”
Dr. Wamhoff is co-founder of HemoShear and co-inventor of its technology. He is an Associate Professor at the University of Virginia (UVa) in the Cardiovascular Division of UVa’s Department of Medicine, with a joint appointment in Biomedical Engineering. Dr. Wamhoff has expertise in small and large animal models of vascular disease, molecular biology and cell-based systems and interventional vascular device development. He has obtained funding from the NIH, the pharmaceutical industry, the American Heart Association, and other organizations to study fundamental mechanisms that regulate smooth muscle cell biology vascular disease. Dr. Wamhoff has authored more than 50 peer-reviewed manuscripts, as well as several book chapters and commentaries. Dr. Wamhoff has also received multiple awards for his successes, including the 2004 American Physiological Society Cardiovascular Young Investigator Award, the 2008 Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Irvine H. Page Award, the 2010 American Physiological Society New Investigator Award for Cardiovascular Research and the 2011 Rhodes College Distinguished Alumni Award, his alma mater. Dr. Wamhoff obtained a BS in Biology with a minor in Business Administration from Rhodes College in 1996 and received his PhD in Medical Physiology from the University of Missouri in 2001.
For a list of publications by Brian R. Wamhoff, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=wamhoff%20b
Vincent E. Aurentz
Chief Business Officer
“I was immediately attracted by the great people and breakthrough technology at HemoShear. This is the recipe for true innovation. We have the ability to truly make a difference in success rates and improve new drug R&D productivity.”
Mr. Aurentz joined HemoShear in July 2013 as Chief Business Officer. He is responsible for commercial business development, where he is expanding HemoShear’s relationships to executive levels within our partners and leads the negotiation of major partnerships and drug R&D agreements. Mr. Aurentz has worked over 24 years in the life sciences industry. Prior to joining HemoShear, Mr. Aurentz was Executive Vice President of the Customer Solutions Business at Quintiles where he created a new business model to strategically engage their customers. Prior to Quintiles, Mr. Aurentz was Executive Vice President at Merck KGaA and was Executive Vice President, Portfolio Development, for Merck Serono. He was a member of the Merck Serono Executive Management Board. He is former co-founder and Managing Director of True North Partners, a venture capital and advisory business focused on the healthcare industry. He currently serves as Chairman of Dovetail Integrated Systems Mr. Aurentz obtained a BS degree in Mathematics from Villanova University.
Nicole E. Hastings, Ph.D.
Vice President of Operations
“We never slow down with regards to improving our knowledge, our science, and our processes. Supporting and impacting research programs worldwide is truly a rewarding endeavor.”
Dr. Hastings obtained her Ph.D. from the Department of Biomedical Engineering at the University of Virginia, where her research focused on elucidating mechanisms of cross-talk and phenotypic modulation of endothelial and smooth muscle cells during initiating stages of atherosclerosis. In developing the foundation for HemoShear’s vascular system, she created a novel in vitro-based human endothelial and smooth muscle co-culture model that applies hemodynamic forces derived from human blood vessels. At HemoShear, she currently oversees all laboratory operations and growth and further supports VABIO, the statewide biotechnology trade organization, as a member and local chair. Dr. Hastings is first author on two peer-reviewed publications, is co-author on five additional high-impact publications, and has presented at various international meetings. Prior to obtaining her Ph.D. at UVa, she obtained a bachelor’s degree in Biomedical Engineering from North Carolina State University.
For a list of publications by Nicole Hastings, Ph.D., go to http://www.ncbi.nlm.nih.gov/pubmed?term=hastings%20ne.
Richard O. White, III, CPA
Vice President Finance & Controller
“What an exciting time to be involved in transforming the productivity of the pharmaceutical industry with HemoShear’s innovative, predictive science!”
Mr. White is a CPA and tax professional. Prior to joining HemoShear in 2012, he had been HemoShear’s public accountant since the Company’s formation in 2008. Mr. White was managing partner of the Charlottesville office of Keiter, Stephens, Hurst, Gary & Shreaves, a 140 person, regional, public accounting firm. His practice included many high-potential, early-stage companies in the central Virginia area. Mr. White’s tax expertise includes corporate structure, capitalization, financing and partnership tax law. He is a Visiting Executive Lecturer at the University of Virginia Darden School of Business and is an advisor to the Batten Incubator, Darden business plan competition and Darden Entrepreneurial Bootcamp. He was one of the original organizers in 1998 of the Virginia Piedmont Technology Council, now called Charlottesville Business Innovation Council (CBIC), and a founding member of Charlottesville Venture Group (CVG).